Skip to main content
NASDAQ:AVIR

Atea Pharmaceuticals Competitors

$19.74
-0.95 (-4.59 %)
(As of 05/12/2021 04:00 PM ET)
Add
Compare
Today's Range
$19.39
$21.05
50-Day Range
$19.63
$77.35
52-Week Range
$18.80
$94.17
Volume558,391 shs
Average Volume506,378 shs
Market Capitalization$1.63 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Atea Pharmaceuticals (NASDAQ:AVIR) Vs. PRGO, SRPT, BPMC, ALLK, IONS, and TGTX

Should you be buying AVIR stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Atea Pharmaceuticals, including Perrigo (PRGO), Sarepta Therapeutics (SRPT), Blueprint Medicines (BPMC), Allakos (ALLK), Ionis Pharmaceuticals (IONS), and TG Therapeutics (TGTX).

Perrigo (NYSE:PRGO) and Atea Pharmaceuticals (NASDAQ:AVIR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Institutional & Insider Ownership

82.7% of Perrigo shares are held by institutional investors. 0.3% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Perrigo and Atea Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Perrigo03102.25
Atea Pharmaceuticals00403.00

Perrigo currently has a consensus price target of $52.00, suggesting a potential upside of 13.17%. Atea Pharmaceuticals has a consensus price target of $69.3333, suggesting a potential upside of 250.70%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Atea Pharmaceuticals is more favorable than Perrigo.

Valuation & Earnings

This table compares Perrigo and Atea Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.84 billion1.26$146.10 million$4.0311.35
Atea PharmaceuticalsN/AN/AN/AN/AN/A

Perrigo has higher revenue and earnings than Atea Pharmaceuticals.

Profitability

This table compares Perrigo and Atea Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Perrigo-0.13%9.78%4.92%
Atea PharmaceuticalsN/AN/AN/A

Summary

Perrigo beats Atea Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Atea Pharmaceuticals (NASDAQ:AVIR) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Insider and Institutional Ownership

89.7% of Sarepta Therapeutics shares are held by institutional investors. 5.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations for Atea Pharmaceuticals and Sarepta Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atea Pharmaceuticals00403.00
Sarepta Therapeutics191302.52

Atea Pharmaceuticals currently has a consensus price target of $69.3333, suggesting a potential upside of 250.70%. Sarepta Therapeutics has a consensus price target of $150.3810, suggesting a potential upside of 104.38%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Atea Pharmaceuticals is more favorable than Sarepta Therapeutics.

Earnings & Valuation

This table compares Atea Pharmaceuticals and Sarepta Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atea PharmaceuticalsN/AN/AN/AN/AN/A
Sarepta Therapeutics$380.83 million15.48$-715,080,000.00($9.71)-7.61

Atea Pharmaceuticals has higher earnings, but lower revenue than Sarepta Therapeutics.

Profitability

This table compares Atea Pharmaceuticals and Sarepta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atea PharmaceuticalsN/AN/AN/A
Sarepta Therapeutics-121.30%-61.62%-23.02%

Summary

Atea Pharmaceuticals beats Sarepta Therapeutics on 5 of the 9 factors compared between the two stocks.

Atea Pharmaceuticals (NASDAQ:AVIR) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for Atea Pharmaceuticals and Blueprint Medicines, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atea Pharmaceuticals00403.00
Blueprint Medicines06712.64

Atea Pharmaceuticals currently has a consensus price target of $69.3333, suggesting a potential upside of 250.70%. Blueprint Medicines has a consensus price target of $113.00, suggesting a potential upside of 21.71%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Atea Pharmaceuticals is more favorable than Blueprint Medicines.

Earnings & Valuation

This table compares Atea Pharmaceuticals and Blueprint Medicines' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atea PharmaceuticalsN/AN/AN/AN/AN/A
Blueprint Medicines$66.51 million80.39$-347,690,000.00($7.27)-12.61

Atea Pharmaceuticals has higher earnings, but lower revenue than Blueprint Medicines.

Profitability

This table compares Atea Pharmaceuticals and Blueprint Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atea PharmaceuticalsN/AN/AN/A
Blueprint Medicines41.08%43.72%33.35%

Summary

Blueprint Medicines beats Atea Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

Atea Pharmaceuticals (NASDAQ:AVIR) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Profitability

This table compares Atea Pharmaceuticals and Allakos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atea PharmaceuticalsN/AN/AN/A
AllakosN/A-29.18%-27.70%

Insider and Institutional Ownership

65.4% of Allakos shares are held by institutional investors. 44.8% of Allakos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Atea Pharmaceuticals and Allakos' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atea PharmaceuticalsN/AN/AN/AN/AN/A
AllakosN/AN/A$-85,370,000.00($1.89)-52.32

Analyst Recommendations

This is a breakdown of recent recommendations for Atea Pharmaceuticals and Allakos, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atea Pharmaceuticals00403.00
Allakos00403.00

Atea Pharmaceuticals currently has a consensus price target of $69.3333, suggesting a potential upside of 250.70%. Allakos has a consensus price target of $181.50, suggesting a potential upside of 82.47%. Given Atea Pharmaceuticals' higher possible upside, equities research analysts clearly believe Atea Pharmaceuticals is more favorable than Allakos.

Summary

Atea Pharmaceuticals beats Allakos on 3 of the 5 factors compared between the two stocks.

Atea Pharmaceuticals (NASDAQ:AVIR) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares Atea Pharmaceuticals and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atea PharmaceuticalsN/AN/AN/A
Ionis Pharmaceuticals7.82%6.57%3.39%

Insider & Institutional Ownership

84.1% of Ionis Pharmaceuticals shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Atea Pharmaceuticals and Ionis Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atea PharmaceuticalsN/AN/AN/AN/AN/A
Ionis Pharmaceuticals$1.12 billion4.68$303.26 million$2.0817.94

Ionis Pharmaceuticals has higher revenue and earnings than Atea Pharmaceuticals.

Analyst Ratings

This is a breakdown of recent ratings for Atea Pharmaceuticals and Ionis Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atea Pharmaceuticals00403.00
Ionis Pharmaceuticals18602.33

Atea Pharmaceuticals presently has a consensus target price of $69.3333, suggesting a potential upside of 250.70%. Ionis Pharmaceuticals has a consensus target price of $57.5909, suggesting a potential upside of 54.52%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Atea Pharmaceuticals is more favorable than Ionis Pharmaceuticals.

Summary

Ionis Pharmaceuticals beats Atea Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

Atea Pharmaceuticals (NASDAQ:AVIR) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Insider & Institutional Ownership

65.7% of TG Therapeutics shares are held by institutional investors. 13.2% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Atea Pharmaceuticals and TG Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atea Pharmaceuticals00403.00
TG Therapeutics01502.83

Atea Pharmaceuticals presently has a consensus target price of $69.3333, suggesting a potential upside of 250.70%. TG Therapeutics has a consensus target price of $63.3333, suggesting a potential upside of 71.54%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Atea Pharmaceuticals is more favorable than TG Therapeutics.

Profitability

This table compares Atea Pharmaceuticals and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atea PharmaceuticalsN/AN/AN/A
TG Therapeutics-151,798.69%-223.96%-108.08%

Valuation & Earnings

This table compares Atea Pharmaceuticals and TG Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atea PharmaceuticalsN/AN/AN/AN/AN/A
TG Therapeutics$150,000.0034,263.55$-172,870,000.00($1.83)-19.85

Atea Pharmaceuticals has higher earnings, but lower revenue than TG Therapeutics.

Summary

Atea Pharmaceuticals beats TG Therapeutics on 5 of the 9 factors compared between the two stocks.


Atea Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Perrigo logo
PRGO
Perrigo
2.2$45.76-3.1%$5.92 billion$4.84 billion-762.54Earnings Announcement
Unusual Options Activity
News Coverage
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$73.89-3.9%$5.67 billion$380.83 million-9.45Earnings Announcement
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$91.65-2.3%$5.47 billion$66.51 million16.91
Allakos logo
ALLK
Allakos
1.7$98.89-0.2%$5.30 billionN/A-36.09Earnings Announcement
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$37.31-1.7%$5.26 billion$1.12 billion77.73Earnings Announcement
Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$36.33-3.3%$5.14 billion$150,000.00-17.14Earnings Announcement
Unusual Options Activity
Galapagos logo
GLPG
Galapagos
1.3$74.14-0.7%$4.82 billion$1.00 billion-11.23Analyst Report
Gap Down
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$68.27-3.2%$4.37 billionN/A-5.56Earnings Announcement
Analyst Report
Unusual Options Activity
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$73.88-0.4%$4.34 billion$6.87 million-7.14Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.6$59.68-3.5%$4.32 billion$85.54 million0.00Analyst Report
News Coverage
I-Mab logo
IMAB
I-Mab
1.2$62.07-5.3%$4.25 billion$4.31 million-2.15
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$54.32-3.4%$3.93 billion$117.91 million-11.02
LEGN
Legend Biotech
1.3$30.35-2.7%$3.93 billion$64.39 million0.00
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$61.23-2.4%$3.80 billion$806.43 million-8.67Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$23.70-7.7%$3.80 billion$204.89 million-29.63
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$46.59-0.1%$3.75 billionN/A-6.28
Alkermes logo
ALKS
Alkermes
1.2$22.44-0.4%$3.60 billion$1.17 billion-48.78
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$115.68-0.4%$3.39 billionN/A-57.55Earnings Announcement
Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.57-3.9%$3.39 billion$114.62 million-7.49Earnings Announcement
Analyst Report
Analyst Revision
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.83-4.5%$3.34 billion$339.08 million-12.69Analyst Report
Analyst Revision
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$65.94-1.5%$3.24 billionN/A-18.79Earnings Announcement
Analyst Upgrade
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$58.60-0.3%$3.15 billion$1.11 billion18.84Analyst Report
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$37.54-1.1%$3.05 billion$60,000.00-11.66Earnings Announcement
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$81.62-1.8%$3.01 billion$26.52 million-7.19Earnings Announcement
Arvinas logo
ARVN
Arvinas
1.7$63.01-2.7%$3.00 billion$42.98 million-24.61
Insmed logo
INSM
Insmed
1.2$26.46-1.9%$2.79 billion$136.47 million-10.18Earnings Announcement
Analyst Report
Unusual Options Activity
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.14-0.1%$2.76 billion$644.77 million-10.29Upcoming Earnings
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$38.29-1.2%$2.73 billion$306.98 million-5.48
MorphoSys logo
MOR
MorphoSys
0.3$19.95-2.0%$2.68 billion$80.43 million95.00News Coverage
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.3$61.98-2.0%$2.67 billion$421.03 million21.82Analyst Report
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$41.61-1.1%$2.57 billionN/A-22.86Earnings Announcement
Gap Up
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$58.91-2.1%$2.49 billionN/A0.00
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.22-4.1%$2.45 billion$182.24 million-8.02Earnings Announcement
ALX Oncology logo
ALXO
ALX Oncology
1.9$54.68-10.8%$2.44 billionN/A0.00
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.7$20.61-0.8%$2.39 billion$306.49 million23.16Earnings Announcement
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.8$36.60-3.3%$2.35 billion$2.11 million-7.92Analyst Report
Analyst Revision
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$46.59-1.1%$2.35 billion$963.01 million14.47Earnings Announcement
Analyst Report
Analyst Revision
Cryoport logo
CYRX
Cryoport
1.7$51.27-10.3%$2.34 billion$33.94 million-88.40Analyst Report
Analyst Revision
Gap Down
Organogenesis logo
ORGO
Organogenesis
1.0$17.18-4.3%$2.30 billion$260.98 million-286.33Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
OPKO Health logo
OPK
OPKO Health
1.9$3.33-2.7%$2.29 billion$901.90 million-18.50Insider Buying
Xencor logo
XNCR
Xencor
1.6$37.92-1.8%$2.25 billion$156.70 million-27.09Earnings Announcement
Analyst Report
Analyst Revision
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$132.71-0.1%$2.20 billionN/A-11.99Earnings Announcement
Analyst Revision
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$125.35-4.1%$2.17 billion$120.28 million-126.62Analyst Report
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$57.01-0.0%$2.14 billionN/A-21.19Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$65.90-0.3%$2.12 billionN/A-28.04Earnings Announcement
News Coverage
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.7$27.92-2.9%$2.09 billion$103.54 million-20.99Earnings Announcement
Analyst Revision
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$25.72-4.4%$2.07 billion$23.90 million-15.98Earnings Announcement
Analyst Revision
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.98-6.2%$2.04 billion$34.51 million-17.93Analyst Report
News Coverage
Gap Down
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.7$29.15-1.4%$2.04 billion$15 million-15.26Analyst Downgrade
Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.93-2.1%$1.95 billion$410,000.00-6.07Earnings Announcement
Analyst Report
News Coverage
This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.